share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股變動聲明-高管 Kulkarni Samarth
美股SEC公告 ·  08/13 06:46

牛牛AI助理已提取核心訊息

CRISPR Therapeutics AG's CEO, Samarth Kulkarni, has completed a transaction involving the company's common stock on 08/08/2024. The action taken was classified as a bona fide gift, with Kulkarni disposing of 100,000 shares at no cost. Following this transaction, Kulkarni directly holds 222,500 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transaction has been reported as completed.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, has completed a transaction involving the company's common stock on 08/08/2024. The action taken was classified as a bona fide gift, with Kulkarni disposing of 100,000 shares at no cost. Following this transaction, Kulkarni directly holds 222,500 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transaction has been reported as completed.
CRISPR Therapeutics AG的首席執行官Samarth Kulkarni已於2024年08/08完成了一項涉及該公司普通股的交易。所採取的行動被歸類爲真實禮物，Kulkarni免費處置了100,000股。在此交易之後，Kulkarni直接持有CRISPR Therapeutics的222,500股。此外，Kulkarni還通過Kulkarni 2023 GRAt間接擁有85,622股股份。該交易已被報告爲已完成。
CRISPR Therapeutics AG的首席執行官Samarth Kulkarni已於2024年08/08完成了一項涉及該公司普通股的交易。所採取的行動被歸類爲真實禮物，Kulkarni免費處置了100,000股。在此交易之後，Kulkarni直接持有CRISPR Therapeutics的222,500股。此外，Kulkarni還通過Kulkarni 2023 GRAt間接擁有85,622股股份。該交易已被報告爲已完成。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間